BPC-157 for Interstitial Cystitis: The 12-Woman Pilot

Say you have lived with bladder pain syndrome for two years. You know every restroom on your commute, you have cut coffee and citrus, and the prescription pill your doctor tried did little. Then a wellness clinic newsletter describes a procedure in which BPC-157 is placed into the bladder wall during a scope exam and presents it as an option for stubborn cases. Is there real evidence behind that offer?

Here is the direct answer. One small human report exists: a pilot study of 12 women at a single private clinic, with no placebo or comparison group, scored by the patients’ own ratings. That is an early signal worth a proper trial, not proof that the procedure works, and BPC-157 is not approved by the U.S. Food and Drug Administration for any use.

What bladder pain syndrome is, and what usually helps

The National Institute of Diabetes and Digestive and Kidney Diseases describes interstitial cystitis, also called bladder pain syndrome, as a long-lasting condition that causes painful urinary symptoms, and estimates that between 4 and 12 million people in the United States may have it. Symptoms vary from person to person and can come and go over time.

MedlinePlus notes that the condition is far more common in women, that its cause is unknown, and that there is no cure. It also says treatments help most people feel better. The list includes stretching the bladder with fluid, rinsing the inside of the bladder with a medicine solution, oral medicines, electrical nerve stimulation, physical therapy, bladder training, lifestyle changes, and, rarely, surgery.

What the 12-woman pilot reported, and its limits

The study, by Lee, Walker, and Ayadi, appeared in Alternative Therapies in Health and Medicine in October 2024. It enrolled 12 women aged 39 to 76 at a private clinic. None had responded to pentosan polysulfate, an approved oral medicine for the condition. During a single cystoscopy, each woman received BPC-157 made by a 503A compounding pharmacy, placed around inflamed areas of the bladder.

Results were measured with the Global Response Assessment, a questionnaire in which patients rate how much better they feel. Ten of the 12 women rated their improvement at 100 percent, and the other two at 80 percent. No one dropped out, and the authors reported no adverse events.

Every woman in the study received the procedure, and the published summary describes no placebo or comparison group. Because bladder pain often waxes and wanes, and because people who know they received a new treatment may expect to feel better, self-rated improvement without a comparison group is hard to interpret. Twelve people at one clinic is also a very small sample.

A 2026 review of BPC-157 in the International Journal of Molecular Sciences puts this study in context. It found human research limited to small pilot studies on musculoskeletal pain, bladder pain, and intravenous use, all suggesting potential benefit without reported major side effects, but it also pointed to inconsistent preparation standards, limited clinical validation, and the absence of randomized controlled trials. The reviewers wrote that comprehensive evaluation is still needed before clinical use can be recommended.

The FDA, for its part, lists BPC-157 among bulk drug substances that may present significant safety risks in compounding. The agency says compounded BPC-157 may pose immune-reaction risks for certain routes and that it has little or no safety information for the proposed routes of administration.

A research-catalog vial of BPC-157 is a laboratory material, and it is not the compounded product used in that clinic. Neither one is an established bladder treatment.

What to do before saying yes

Ask your urologist or urogynecologist which standard options you have not yet tried, including bladder instillations, nerve stimulation, and physical therapy. If a clinic pitches BPC-157, ask whether the procedure is part of a registered clinical trial with a comparison group, who makes the product, and what happens if something goes wrong. You can also search ClinicalTrials.gov for interstitial cystitis studies that are enrolling. A registered, controlled trial is the place where a promising idea like this one gets a fair test.

Not medical advice.

Bladder Pain Syndrome and a BPC-157 Offer: What a 12-Woman Pilot Showed

What bladder pain syndrome is, and what usually helps

What the 12-woman pilot reported, and its limits

What to do before saying yes

Sources

Related reading

Share this:

Like this: